Cargando…
COVID-19 infection in severe Alpha 1-antitrypsin deficiency: Looking for a rationale
The clinical manifestations of COVID-19 are heterogeneous: 46.4% of patients admitted into hospital reported to have at least one comorbidity. Comorbidities such as COPD, diabetes, hypertension and malignancy predispose patients with Covid-19 to adverse clinical outcomes. Alpha 1-antitrypsin deficie...
Autores principales: | Ferrarotti, I., Ottaviani, S., Balderacchi, A.M., Barzon, V., De Silvestri, A., Piloni, D., Mariani, F., Corsico, A.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086383/ https://www.ncbi.nlm.nih.gov/pubmed/33964815 http://dx.doi.org/10.1016/j.rmed.2021.106440 |
Ejemplares similares
-
Improving the Laboratory Diagnosis of M-like Variants Related to Alpha1-Antitrypsin Deficiency
por: Barzon, Valentina, et al.
Publicado: (2022) -
Molecular diagnosis of alpha1‐antitrypsin deficiency: A new method based on Luminex technology
por: Ottaviani, Stefania, et al.
Publicado: (2020) -
Update on α(1)-antitrypsin deficiency
por: Ferrarotti, Ilaria, et al.
Publicado: (2018) -
Case-finding for alpha1-antitrypsin deficiency in Kazakh patients with COPD
por: Zhumagaliyeva, Ardak, et al.
Publicado: (2017) -
Adipose Mesenchymal Extracellular Vesicles as Alpha-1-Antitrypsin Physiological Delivery Systems for Lung Regeneration
por: Bari, Elia, et al.
Publicado: (2019)